Year: 2018
Type: article
Abstract: // David M. Goldenberg 1, 2 , Rhona Stein 1 and Robert M. Sharkey 1, 3 1 Center for Molecular Medicine and Immunology, Belleville, NJ, USA 2 IBC Pharmaceuticals, Inc., Morris Plains, NJ, USA 3 Immunomedics, Inc., Morris Plains, NJ, USA Correspondence to: David M. Goldenberg, email: [email protected] Keywords: TROP-2; TACSTD2; sacituzumab govitecan; antibody-drug conjugates; immunotherapy Received: April 30, 2018 Accepted: May 31, 2018 Published: June 22, 2018 ABSTRACT TROP-2 is a glycoprotein first described as a surface marker of trophoblast cells, but subsequently shown to be increased in many solid cancers, with lower expression in certain normal tissues. It regulates cancer growth, invasion and spread by several signaling pathways, and has a role in stem cell biology and other diseases. This review summarizes TROP-2’s properties, especially in cancer, and particularly its role as a target for antibody-drug conjugates (ADC) or immunotherapy. When the irinotecan metabolite, SN-38, is conjugated to a humanized anti-TROP-2 antibody (sacituzumab govitecan), it shows potent broad anticancer activity in human cancer xenografts and in patients with advanced triple-negative breast, non-small cell and small-cell lung, as well as urothelial cancers.
Source: Oncotarget
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Awards: G1401682256, G9000061820, G9000352052
OpenAlex ID: W2809327804